Published July 3, 2018
| Version v1
Dataset
Open
The process of HDAC11 Assay Development: Effect of reducing agent
Description
An effect of adding reducing agent on the HDAC11 activity was monitored.
Notes
The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files
3july2018-HDAC11-reducing agent.pdf
Files
(94.1 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:3ad64d7c8ef149aba97bd4539c1f9f8f
|
94.1 kB | Preview Download |